Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 18/20 | 0.50 |
| ▸ | CDK12 | Q9NYV4 | 18/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 17/20 | 0.50 |
| ▸ | CDK9 | P50750 | 17/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.50 |
| ▸ | CDK2 | P24941 | 14/20 | 0.50 |
| ▸ | CDK7 | P50613 | 11/20 | 0.46 |
| ▸ | CCNH | P51946 | 10/20 | 0.46 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269583 | 1.00 | CCNK (0.50) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL17961848 | 0.90 | CCNT1 (0.41) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL17961847 | 0.90 | CCNT1 (0.41) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL24695415 | 0.83 | CCNT1 (0.47) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL30259588 | 0.81 | KDM4E (0.61) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL12237657 | 0.81 | KDM4E (0.59) | — | |
| SCHEMBL10187962 | 0.81 | KDM4E (0.53) | CCNKCDK12 | |
| SCHEMBL25222649 | 0.80 | IDH2 (0.56) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL25258456 | 0.80 | IDH2 (0.56) | CCNKCDK12CCNT1CDK9CCNE1 | |
| SCHEMBL28312479 | 0.80 | IDH2 (0.56) | CCNKCDK12CCNT1CDK9CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133901-B2 | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| EP-2094685-B1 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2094685-A2 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008065626-A2 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVESAS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | HCRTR1, HCRTR2, NPY1R | CCNK 2134/4885CDK12 1669/4885CCNT1 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.